BRCA2 and ovarian cancer: SNRPB knockdown inhibited ovarian cancer cell proliferation, downregulated DNA replication and HR genes, and promoted aberrant BRCA2 exon 3 skipping, leading to a loss of the PALB2 binding domain and further impairment of HR.